Lp(a): A Toolkit for Health Care Professionals

21 REFERENCES 1 Shapiro et al. 2019, Lipoprotein(a) Removal Still a Mystery, https:// doi.org/10.1161/JAHA.118.011903J ournal of the American Heart Association. 2019;8 2 Tsimikas S, Stroes ESG. Atherosclerosis. 2020;300:1-9 3 Grundy, Scott M., Stone, Neil J., Bailey, Alison L., Beam, Craid, Birtcher, Kim K., Blumenthal, Roger. S., Braun, Lynne T., de Ferranti, Sarah, Faiella-Tommasino, Joseph; Foman, Daniel E.; Goldberg, Ronals; Heidenreich, Paul A.; Hlatky, Mark A.; Jones, Daniel W.; Lloyd-Jones, Donald; Lopez-Pajares, Nuria; Ndumele, Chiadi E., Orringer, Carl E.; Peralta, Carmen A.; Saseen, Joseph J.; Smith, Jr., Sidney C.; Sperling, Laurence; Virani, Salim S.; Yeboah, Joseph, Circulation, AHA Journals, 10 Nov 2018; 2019;139:e1082–e1143 4 Bucci M, Tana C, Giamberardino MA, Cipollone F. Lp(a) and cardiovascular risk: Investigating the hidden side of the moon. Nutr Metab Cardiovasc Dis. 2016 Nov; 26(11):980-986. doi: 10.1016/j. numecd.2016.07.004. Epub 2016 Jul 12. PMID: 27514608 https://pubmed.ncbi.nlm.nih.gov/27514608/ 5 AHA Lipoprotein(a) and Low-density lipoprotein cholesterol (LDL-C) Needs Assessment. 6 Don P. Wilson, MD*, Terry A. Jacobson, MD, Peter H. Jones, MD, Marlys L. Koschinsky, PhD, Catherine J. McNeal, MD, PhD, Børge G. Nordestgaard, MD, DMSc, Carl E. Orringer, MD, Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association, Journal of Clinical Lipidology (2019) 13, 374-392. https://pubmed. ncbi.nlm.nih.gov/31147269/ 7 Likozar AR, Zavrtanik M, Sebestjen M. Lipoprotein(a) in atherosclerosis: From pathophysiology to clinical relevance and treatment options. Ann Med. 2020;52(5):162-177 8 Lp(a) and Familial Hypercholesterolemia; FH Foundation. 9 Jawi MM, Frohlich J, Chan SY. Lipoprotein(a) the insurgent: A new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule. J Lipids. 2020;2020:3491764. 10 Tsimikas S. Lp(a) as a new target for reduction of risk of cardiovascular disease and emergence of novel therapies to lower Lp(a). Curr Opin Endocrinol Diabetes Obes. 2016;23(2):157-164. 11 Wang W, Hu D, Lee ET, et al. Lipoprotein(a) in American Indians is Low and Not Independently Associated with Cardiovascular Disease. The Strong Heart Study. Ann Epidemiol. 2002;12(2):107- 114. https://pubmed.ncbi.nlm.nih.gov/11880218/ 12 Duncan MS, Vasan RS, Xanthakis V. Trajectories of blood lipid concentrations over the adult life course and risk of cardiovascular disease and all-cause mortality: Observations from the Framingham Study over 35 years. J Am Heart Assoc. 2019;8(11):e011433. 13 Mehdi Afshar, Louise Pilote, Line Dufresne, James C. Engert, and George Thanassoulis. Lipoprotein(a) Interactions With Low- Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS). https:// doi.org/10.1161/JAHA.115.003012Journal of the American Heart Association. ;5:e003012 14 AHA Guidelines 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines | Circulation (ahajournals.org) 15 Sebhat Erqou, Stephen Kaptoge, Philip L Perry, Emanuele Di Angelantonio, Alexander Thompson, Ian R White, Santica M Marcovina, Rory Collins, Simon G Thompson, John Danesh. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. PMID: 19622820 PMCID: PMC3272390 DOI: 10.1001/jama.2009.1063 16 Hu, X., Yang, X., Li, X. et al. Lipoprotein (a) as a residual risk factor for atherosclerotic renal artery stenosis in hypertensive patients: a hospital-based cross-sectional study. Lipids Health Dis 19, 173 (2020). https://doi.org/10.1186/s12944-020-01272-0 17 Dhindsa DS, Sandesara PB, Shapiro MD, Wong ND. The evolving understanding and approach to residual cardiovascular risk management. Front Cardiovasc Med. 2020;7:88. 18 Reference: FDA Approval/IFU4.21.2020 19 Paul Scheel, MD, Joseph Meyer, MD; Roger S. Blumenthal, MD, FACC; Seth Shay Martin, MD, MHS, FACC; Lipoprotein(a) in Clinical Practice. American College of Cardiology. July 2, 2019. 20 Lars Berglund, Rajasekhar Ramakrishnan, Lipoprotein(a): An Elusive Cardiovascular Risk Factor, AHA Journals, December, 2004, Vol. 24, Issue 12, https://www.ahajournals.org/doi/full/10.1161/01. atv.0000144010.55563.63. 21 Guddeti RR, Patil S, Ahmed A, Sharma A, Aboeata A, Lavie CJ, Alla VM. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review. Prog Cardiovasc Dis. 2020 Jul-Aug;63(4):496-502. doi: 10.1016/j.pcad.2020.06.002. Epub 2020 Jun 8. PMID: 32526213. https://pubmed.ncbi.nlm.nih.gov/32526213/ 22 Singh M, McEvoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: The AHA/ACC/Multisociety guidelines vs the ESC/EAS guidelines. Mayo Clin Proc. 2020;95(5):998-1014. https://pubmed.ncbi.nlm.nih.gov/32370858/ 23 Moriarty, Gray, & Gordy Lipoprotein apheresis for lipoprotein (a) and cardiovascular disease. Journal of Clinical Lipidology, Vol. 13(6) Nov-Dec 2019. P 894-900 https://pubmed.ncbi.nlm.nih. gov/31753721/ 24 Josef Leebmann, Eberhard Roeseler, Ulrich Julius, et al. Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease. https://doi.org/10.1161/ CIRCULATIONAHA.113.002432Circulation. 2013;128:2567–2576 25 Michelle L O’Donoghue, David A Morrow, Sotirios Tsimikas, et al. Lipoprotein (a) for risk assessment in patients with established coronary artery disease. PMID: 24161323 PMCID: PMC3945105 DOI: 10.1016/j.jacc.2013.09.042